Amrutanjan Health Care Limited
AMRUTANJAN · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹527.15.
Piotroski F-score 2/9 — quality of earnings & balance sheet.
Investability checklist
- ✓ROE above 15%16.6%
- ✓Low debt (D/E < 0.5)0.00x
- ✓Positive free cash flow
- ✓Revenue growth > 10%11%
- ✓Earnings growing7%
- ✓Net margin ≥ 10%11.5%
- ✓Current ratio > 1.52.31
- ✓Below our fair value
- ✓Margin of safety ≥ 20%
- ✕Above 200-day average
- ✕Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 8.42
- ✕Piotroski ≥ 72/9
1-year price
EOD · 2026-06-16Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Quarterly results
Annual financials
Shareholding
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
SWOT snapshot
Strengths
- •Lightly leveraged balance sheet.
- •Financially solid — Altman Z 8.42.
Weaknesses
- •Price below its 200-day moving average (downtrend).
- •Weak Piotroski score (2/9).
Opportunities
- •Trading in our value buy zone versus sector peers.
- •Trades ~22% below our estimated fair value.
About Amrutanjan Health Care Limited
Amrutanjan Health Care Limited manufactures, supplies, and sells ayurvedic pain balms and women hygiene products in India and internationally. It operates through OTC Products, Beverages, Women's Hygiene, and Others segments. The company provides pain management products comprising pain balms and roll-ons, back pain roll-ons, stick-on patch, and joint muscle sprays; dental pain gel; and decorn corn caps; hand sanitizer under the NOGerms brand name; and fruit and rehydration j
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.